Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.98M | $14.7M | $23.1M | $32.4M | $4.31M | $12.3M | $3.11M | — | — | — |
| Revenue growth | — | 46.8% | 57.4% | 40.6% | -86.7% | 185.3% | -74.7% | — | — | — |
| Operating income | -$139M | -$53.9M | -$51.7M | -$41.0M | -$27.5M | -$21.4M | -$28.6M | -$28.9M | -$24.6M | -$26.3M |
| Operating margin | -1389.8% | -368.1% | -224.0% | -126.3% | -638.1% | -174.1% | -919.7% | — | — | — |
| Net income | -$112M | $6.97M | -$53.7M | -$40.4M | -$17.8M | -$28.5M | $8.03M | -$17.4M | -$24.1M | -$26.0M |
| Net margin | -1125.8% | 47.6% | -232.8% | -124.7% | -411.9% | -231.5% | 257.8% | — | — | — |
| EPS (diluted) | -$5.55 | $0.33 | -$2.39 | -$13.86 | -$5.23 | -$6.07 | $1.57 | -$2,316.83 | -$31,460.23 | -$87.27 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$36.9M | -$41.6M | -$51.4M | -$42.4M | -$29.3M | -$21.7M | -$21.0M | -$11.7M | -$23.8M | -$25.6M |
| Capital expenditures | $2.51M | $1.40M | $976K | $153K | $88.0K | $713K | $29.0K | — | — | — |
| Free cash flow | -$39.4M | -$43.0M | -$52.4M | -$42.5M | -$29.4M | -$22.4M | -$21.1M | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $9.68M | $7.09M | $30.6M | $12.4M | $40.0M | $45.0M | $22.6M | $16.9M | $8.71M | $21.6M |
| Total assets | $91.9M | $117M | $67.5M | $53.4M | $53.5M | $56.6M | $34.2M | $24.8M | $15.6M | $27.2M |
| Total liabilities | $41.3M | $35.0M | $37.1M | $41.6M | $37.0M | $55.4M | $16.2M | $12.6M | $10.8M | $9.81M |
| Long-term debt | $18.4M | $15.7M | $19.3M | — | $28.2M | $16.0M | $4.01M | $0.00 | — | — |
| Shareholders' equity | $50.6M | $82.0M | $30.4M | $11.8M | $16.6M | $1.22M | $18.0M | $12.2M | $4.75M | $17.4M |
| Retained earnings | -$80.7M | -$73.7M | -$127M | -$168M | -$186M | -$214M | -$206M | -$223M | -$248M | -$275M |
| Shares (wtd avg diluted) | 20.3M | 21.6M | 22.8M | 3.23M | 4.41M | 4.69M | 5.10M | 7.51B | 767M | 316K |
Every figure is extracted from Aptevo Therapeutics Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.